Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

"a Phase 4, Postmarketing Study Evaluating The Impact Of Prevnar 13 (Trademark)(13-valent Pneumococcal Conjugate Vaccine; 13vpnc) In Reducing Acute Otitis Media And Nasopharyngeal Colonization Caused By Streptococcus Pneumoniae In Healthy Children

NCT01199016 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01199016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01199016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
"a Phase 4, Postmarketing Study Evaluating The Impact Of Prevnar 13 (Trademark)(13-valent Pneumococcal Conjugate Vaccine; 13vpnc) In Reducing Acute Otitis Media And Nasopharyngeal Colonization Caused By Streptococcus Pneumoniae In Healthy Children
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
September 30, 2010
Completion date
January 31, 2016
Enrollment
239 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

otitis media